Sun Pharmaceutical Industries First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Sun Pharmaceutical Industries (NSE:SUNPHARMA) First Quarter 2025 Results

Key Financial Results

• Revenue: ₹126.5b (up 6.0% from 1Q 2024).
• Net income: ₹28.4b (up 40% from 1Q 2024).
• Profit margin: 22% (up from 17% in 1Q 2024). The increase in margin was primarily driven by higher revenue.
• EPS: ₹11.80 (up from ₹8.40 in 1Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sun Pharmaceutical Industries EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 1.8%. Earnings per share (EPS) exceeded analyst estimates by 10%.

Looking ahead, revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India.

Performance of the Indian Pharmaceuticals industry.

The company's shares are up 1.0% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Sun Pharmaceutical Industries that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com